New Rat Model of Autoimmune Diabetes And Arthritis
DESCRIPTION (provided by applicant): The objectives of this proposal are to
develop and characterize a new congenic rat model with spontaneous autoimmune
disease. In Phase 1 we will establish a foundation colony of LEW.1WR1 rats and
begin genetic crosses to introgress traits from BBDR/Wor and LEW.1WR strains.
This should increase the incidence of spontaneous diabetes and may induce
spontaneous arthritis and thyroiditis. The incidence and age of onset of type 1
diabetes, and the occurrence of spontaneous arthritis will be monitored. In
Phase 2, select Quantitative Trait Loci (QTL) markers will be used to construct
speed a congenic strain with a high incidence of multiple spontaneous
Some 5 percent of the U.S. population is affected by one or more autoimmune
diseases. Experimental animal models facilitate the study of the pathogenesis
of autoimmune diseases and permit the evaluation of treatment protocols that
are not immediately feasible or ethical in humans. Animal models also provide
populations of genetically uniform subjects that can be maintained under
environmentally controlled conditions. It is our expectation that this new
model of autoimmunity will expedite the development of safe and effective
pharmaceutical agents for the treatment of Rheumatoid Arthritis, Type 1
Diabetes, and Hashimoto's Thyroiditis.
PROPOSED COMMERCIAL APPLICATION:
This research effort will result in a new characterized model of autoimmune diseases. The
animal model will generate income by direct sales and contract research within the 15,000
sq. ft. BRM facility.
Small Business Information at Submission:
Principal Investigator:Dennis L. Guberski
BIOMEDICAL RESEARCH MODELS, INC.
10 NEW BOND ST WORCESTER, MA 01606
Number of Employees: